Shotlee LogoShotlee
🛡️ Immune Support✅ Clinical Approvals📊 Updated 2026

Best Peptide for Immune System

Thymosin Alpha-1, LL-37, Thymalin & Epithalon — Ranked for Immune Function (2026)

Immune-optimising peptides work through distinct arms of the immune system: Thymosin Alpha-1 restores adaptive T-cell immunity (the most clinically validated, approved in 35+ countries); LL-37 strengthens innate antimicrobial defence; Thymalin regenerates thymic function depleted by aging; Epithalon reverses immune aging via telomere maintenance. Choosing the right immune peptide depends on whether the deficit is adaptive, innate, or aging-related. Track your immune protocol in Shotlee.

Download on theApp Store
Get it onGoogle Play

Top Immune System Peptides — Ranked by Evidence

PeptideImmune Arm TargetedBest EvidenceStatusEvidence Level
Thymosin Alpha-1Adaptive: T-cell maturation, NK cell activation, Th1 cytokinesApproved in 35+ countries for hepatitis B/C, cancer adjunct, HIVApproved (Zadaxin); research use in US/UK⭐⭐⭐⭐⭐
LL-37Innate: cathelicidin antimicrobial, TLR modulation, pathogen defenceHuman innate immunity studies; respiratory/wound infection dataResearch peptide⭐⭐⭐
ThymalinThymic: T-lymphocyte precursor maturation, IL-2, NK activationApproved in Russia for immunodeficiency, HIV, cancer support; Khavinson longevity studiesApproved (Russia); research elsewhere⭐⭐⭐⭐
EpithalonImmune aging: telomere maintenance in immune cells, NK cell activityPhase 2: immune restoration in elderly; NK cell enhancementResearch peptide⭐⭐⭐
KPVAnti-inflammatory: NF-kB inhibition, immune balance, mucosal immunityIBD/skin animal data; gut-immune modulationResearch only⭐⭐
TB-500 (Thymosin Beta-4)Repair: anti-inflammatory during healing, post-infection tissue repairPhase 2 cardiac healing; broad tissue repair dataResearch peptide⭐⭐⭐

Thymosin Alpha-1 has by far the most clinical approval data of any immune peptide. LL-37 is the only human endogenous cathelicidin. Evidence reflects human immune-specific data. [1, 2, 3]

Top Immune Picks Explained

Thymosin Alpha-1 (TA-1) — Adaptive Immunity

The most clinically validated immune peptide. Originally isolated from bovine thymus by Allan Goldstein in the 1970s. Approved as Zadaxin in 35+ countries for hepatitis B/C, cancer immunotherapy adjunct, and primary immunodeficiency. Promotes T-lymphocyte maturation in the thymus, activates NK cells, enhances Th1 cytokine production (IFN-gamma, IL-2), and suppresses Th2-mediated immune dysregulation. Used off-label for longevity, chronic viral infections, and immunosenescence reversal. Standard dose: 1.6 mg SC twice weekly.

LL-37 — Innate Antimicrobial Defence

The only human cathelicidin — an endogenous host defence peptide produced by neutrophils, epithelial cells, and macrophages in response to infection. Kills bacteria by disrupting microbial cell membranes while sparing human cells. Modulates TLR signalling to optimise (not over-stimulate) innate immune responses. Also has antiviral properties studied for respiratory infections. Most relevant for: chronic infections, recurrent respiratory infections, SIBO, wound infections, and innate immune deficiency. Not FDA-approved.

Thymalin — Thymic Regeneration

Derived from bovine thymus and approved in Russia as an immunomodulatory drug. The thymus involutes dramatically with age, producing fewer T cells and causing age-related immunosenescence. Thymalin restores thymic function by stimulating T-lymphocyte precursor differentiation, IL-2 production, and NK cell activity. Khavinson's 40-year longitudinal studies showed Thymalin administration in elderly subjects significantly reduced all-cause mortality and infection rates. Used for cancer chemotherapy support, primary immunodeficiency, and age-related immune optimisation.

Epithalon — Immune Aging

Telomere shortening in immune cells is a key mechanism of immunosenescence — aged immune cells with shortened telomeres have reduced proliferative capacity and impaired function. Epithalon's telomerase-activating mechanism extends the replicative lifespan of T cells and NK cells. Phase 2 data also shows Epithalon enhances NK cell cytotoxicity in elderly subjects. Used as 10-day cycled courses 1–2x per year as part of a comprehensive immune-aging protocol.

KPV — Immune Balance

Alpha-MSH C-terminal tripeptide with direct NF-kB inhibitory activity — reducing pro-inflammatory immune dysregulation without global immunosuppression. Relevant for conditions where over-activated immune responses (autoimmunity, chronic inflammation) are the problem rather than immune deficiency. Used orally for gut-immune conditions (IBD, food sensitivities) and systemically for anti-inflammatory immune balance. Not an immune stimulant — it modulates rather than amplifies immune responses.

How to Choose the Right Immune Peptide

The choice of immune peptide depends on which immune compartment is deficient. For adaptive T-cell immunity deficits — chronic viral infections (HBV, HCV, EBV), cancer support, or T-cell deficiency — Thymosin Alpha-1 is the clear first choice with the most clinical validation. For innate immunity and pathogen defence — recurrent respiratory infections, SIBO, wound infections — LL-37 addresses the first-line antimicrobial response.

For age-related immune decline where thymic involution has reduced T-cell production, Thymalin (available in Russia) or Thymosin Alpha-1 both restore thymic-dependent adaptive immunity. Epithalon adds the telomere-maintenance dimension for immune cell longevity. These can be combined in comprehensive immune-aging protocols.

Note that Thymosin Alpha-1 is approved and has the safety profile of a clinical drug — it is the most evidence-justified immune peptide for most people. Use with physician supervision, particularly for cancer or hepatitis indications. Track your immune biomarkers (CD4/CD8 counts, NK cell activity if available, infection frequency) in Shotlee alongside your protocol to quantify immune improvement.

Track Your Immune Protocol in Shotlee

Log every Thymosin Alpha-1 or immune peptide dose in Shotlee. Track infection episodes, recovery time from illness, and any available immune biomarkers (CD4 counts, CRP) to measure your protocol's impact on immune function.

How to Track Your Immune Protocol in Shotlee

01

Baseline: record current immune status — frequency of illness in past 12 months, any chronic infections, available immune biomarkers (CD4, CD8, NK cell counts, CRP, IgG levels)

02

Log each Thymosin Alpha-1 or immune peptide injection with dose, site, and date — the 2x weekly schedule requires consistent logging

03

Record any illness episodes during the protocol: onset date, severity (1–10), recovery duration — compare to your pre-protocol illness history

04

Track energy levels weekly — immune system restoration often presents first as improved energy and reduced fatigue before measurable biomarker changes

05

Repeat immune biomarker panels at 3 and 6 months and compare to Shotlee baseline entries to quantify the protocol's measurable immune impact

Frequently Asked Questions

Thymosin Alpha-1 (TA-1) is the most clinically validated immune peptide with the strongest human trial evidence — approved in 35+ countries for viral infections, cancer immunotherapy, and immunodeficiency as Zadaxin. For innate immunity and antimicrobial defence, LL-37 is the most targeted choice. For age-related immune decline, Thymalin or TA-1 combined with Epithalon provides both adaptive and cellular longevity support.

TA-1 strengthens immunity via T-cell maturation (undeveloped T-lymphocyte precursors mature into functional CD4+ and CD8+ cells), NK cell cytotoxicity enhancement (cancer and viral cell killing), Th1 cytokine polarisation (IFN-gamma, IL-2 for cell-mediated immunity), and dendritic cell maturation (improving adaptive immune priming). These combined effects explain efficacy across chronic viral hepatitis, cancer immunotherapy support, and COVID-19 severity reduction.

LL-37 targets innate immunity (rapid, non-specific first response to pathogens — best for active infections). Thymosin Alpha-1 targets adaptive immunity (slower, specific T-cell response — best for chronic viral infections, cancer, and long-term immune optimisation). For comprehensive immune support, combining both addresses innate (LL-37) and adaptive (TA-1) immunity simultaneously.

Thymosin Alpha-1 (Zadaxin) has an excellent safety profile in clinical trials spanning decades. It does not cause the severe side effects associated with cytokine therapies or systemic immunosuppressants. Long-term use has been studied in hepatitis B/C protocols and cancer immunotherapy contexts without major safety signals. It requires physician supervision and is a prescription drug in countries where it is approved.

Thymosin Alpha-1 was studied in COVID-19 patients in China with promising results for reducing disease severity. For long-COVID, the immune dysregulation hypothesis suggests TA-1 may help restore normal T-cell function and clear viral reservoirs. LL-37 has antiviral properties relevant to COVID-19. These are research applications without specific FDA approval for long-COVID.

References

  1. [1]ReviewGoldstein AL, Goldstein AL. "From lab to bedside: emerging clinical applications of thymosin alpha 1." Expert Opin Biol Ther. 2009;9(5):593-608.
  2. [2]ReviewZanetti M. "Cathelicidins, multifunctional peptides of the innate immunity." J Leukoc Biol. 2004;75(1):39-48.
  3. [3]Clinical TrialKhavinson VK, et al. "Thymalin prolongs the life span of old mice." Bull Exp Biol Med. 2003;136(2):169-170.

Track Your Immune Protocol in Shotlee

Log every injection, track illness episodes, and monitor immune biomarkers over time. Build the data that shows your immune protocol is working.

🚀 Use Shotlee for Free